 I'm so glad Teri is here because I would have never been able to figure that out. So again, welcome everybody. Teri and I had the honor and privilege of chairing the first of these Genomic Medicine Centers meetings in July in Chicago. And the purpose of this segment of our agenda is just to bring all of those, all of you who are not able to be present at that meeting up to speed on what we chatted about in Chicago and for those of you who were there to remind you of that blur of a day that they went by so quickly. As both Brex and Eric mentioned, the motivation for what we're doing here really emanates from discussions around the strategic planning process for NHGRI and to move genomics both into medical applications and transform healthcare in a significant way, generating greater effectiveness. And I think the questions that we've been asking ourselves, both at Council and I'm sure many of you have been asking at your local institutions, is how are we really going to do this? I think from NHGRI's perspectives we felt that having this type of group come together was a significant opportunity for us to really take a biopsy of what was going on in the field, not necessarily stimulated by any NIH resources, but really homegrown at many institutions, which is something I think that we saw quite a lot of in our Chicago discussions. And then the question is what role should NIH or NHGRI play? And as Eric said, this doesn't necessarily mean a pot of money is going to be thrown at this, but really to do things like we're doing here which is very catalytic and can stimulate some very important discussions and potential collaborations that don't require anything but just sharing information. So in Chicago, roughly 40 of us attended. The obviously many of the institutions listed here were at that meeting and there are many more in the room today which we're very pleased to see, as well as representation from a number of NIH institutes that have a significant interest in the field of genomic medicine and translational genomics. And we took, we thought we might accomplish these three tests at the first meeting. Clearly we were quite ambitious. What we did, I think, successfully do is highlight many translational areas of genomics and that have been applied to genomic medicine. And I think we're going to continue those discussions today. We thought that many of us have been working in this area could be defining those low-hanging fruit types of demonstration projects that would be the quick wins and show the value of translational genomics. And again, I think one of the themes of this meeting is to perhaps articulate better where those demonstration projects should be so that we can be more focused in our activities. And also, there's been some discussions both prior to the Chicago meeting and since then about whether there should be some sort of formalization of this group and Rex alluded to that. And I don't want to call it anything, but we might discuss that a little bit before this meeting is over. We asked, and I don't think we did this coming into this meeting, but coming into the Chicago meeting, we asked the participants to fill out a template that would give us a real sense of the richness of their projects, what the goals were that were taking place at their institution, what the funding sources would be, what the organizational structure would be. And I think all of you have been sent copies of some of the documents that were filled out prior to that meeting so that you have a sense of what was going on. The projects covered that we talked about then and we'll talk about today covered, I think, a wide array of areas ranging from a whole genome sequencing for diagnostic dilemmas to a plethora of pharmacogenomics projects that were targeted at either antiplatelet agents, anti-depressants and psychotropic medications, as well as preemptive pharmacogenomics family history projects as well. And there were a number of other programs that were looking at genotyping for risk assessment, somatic sequencing or genotyping of tumor cells to guide therapies, et cetera. So I think we found that much to our delight and maybe potentially surprised that the range of ongoing projects that were moving either that were actually clinically implemented or moving toward that goal were quite varied and had moved along quite successfully. We also asked the participants to help us understand what the barriers were to implementation research, particularly as it pertains to genomics at their institutions and what solutions they have found. And also we also asked participants to help us understand what role they might foresee NHGRI playing in advancing this strategic agenda. We didn't really have a great deal of time to cover the barriers and solutions, but I think that's going to be embedded in a lot of the initiatives that we're going to be talking about today. But just to highlight a couple of a few of these that those of you at the meeting articulated, clearly the need for evidence that proves the value proposition for what we're doing in genomics of physician and acceptance and institutional leadership acceptance, I know we're going to be talking a little bit about that later on this morning. Education, the whole testing platform and access, clear certification, integration into electronic medical records, which has been the subject of both not only the eMERGE programs at NHGRI, but also some workshops, as well as the question of what's the workforce that's going to be necessary to implement genomics, the whole area of sanitizing and form consent, sample availability and bio-banking, and also who's going to really fund this beyond what we can do locally at our own institution. So I think we've got the grist, I think, for a significant amount of issues that we will be talking about both at this meeting as well as at several of the workshops that Teri is going to highlight for you now. I'm going to turn it over to Teri.